Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset?

The net enactment told a antithetic story. Hims reported an $86.3 cardinal nett loss, adjacent to 37 cents per share, compared with a $42.5 cardinal nett a twelvemonth earlier. Analysts surveyed by LSEG had expected a nonaccomplishment of conscionable 1 cent per share. Gross borderline fell to 64% from 76%.

The marketplace is nary longer asking whether Hims & Hers Health, Inc. (NYSE:HIMS) tin pull weight-loss customers. The branded GLP-1 pivot has already answered that question. The contented is whether those customers, planetary expansion, and personalized attraction tin yet regenerate the unusually charismatic economics of compounded treatments.

BULL CASE

The strongest portion of the 4th was that request survived a large alteration successful the merchandise model.

In March, Hims expanded its branded weight-loss assortment done an statement with Novo Nordisk and stopped broadly advertizing compounded GLP-1 drugs. That could person created a heavy gross gap. Instead, absorption said the branded displacement was a cardinal operator of renewed home growth. U.S. gross accrued 16% twelvemonth implicit twelvemonth to $621.8 million.

Hims & Hers Health, Inc. (NYSE:HIMS) ended the 4th with astir 307,000 much subscribers than it had astatine the extremity of March. Those were consolidated nett additions and included subscribers acquired with Eucalyptus, which joined Hims during June. Even with the acquisition contribution, the summation shows that the level continued expanding during the branded-drug transition.

Monthly Revenue per Average Subscriber reached $92. Hims & Hers Health, Inc. (NYSE:HIMS) calculates the metric utilizing full revenue, truthful it includes one-time purchases arsenic good arsenic gross from Eucalyptus. Excluding Eucalyptus, the fig would person been $90, portion excluding one-time purchases would person reduced the reported magnitude by astir different $10.

That creation makes the metric broader than recurring subscription revenue, but it besides shows however Hims & Hers Health, Inc. (NYSE:HIMS) is monetizing customers done a wider premix of products and transactions. Branded weight-loss drugs make much gross per user, though overmuch of that payment is offset by higher merchandise costs. Management said retention among newer branded weight-loss cohorts was tracking successful enactment with expectations, portion aboriginal users receiving a much immersive app acquisition showed little cancellation rates.